Pembrolizumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
 (pem-broh-LIH-zoo-mab)

This page contains brief information about pembrolizumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Keytruda
FDA Approved
Yes

FDA Approval for Pembrolizumab for Gastric Cancer

FDA Approval for Pembrolizumab for Microsatellite Instability – High/Mismatch Repair Deficient Cancer

FDA Approval for Pembrolizumab for Urothelial Carcinoma

FDA Approval for Pembrolizumab for Non-Small Cell Lung Cancer (2017)

FDA Approval for Pembrolizumab for Hodgkin Lymphoma

FDA Approval for Pembrolizumab for Non-Small Cell Lung Cancer (2016)

FDA Approval for Pembrolizumab for Head and Neck Cancer

FDA Approval for Pembrolizumab for Melanoma (2015)

FDA Approval for Pembrolizumab for Non-Small Cell Lung Cancer (2015)

FDA Approval for Pembrolizumab for Melanoma (2014)

Use in Cancer

Pembrolizumab is approved to treat:

Pembrolizumab is also being studied in the treatment of other types of cancer.

More About Pembrolizumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Pembrolizumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Pembrolizumab Secures FDA Approval in Stomach Cancer

FDA Approves Pembrolizumab for Tumors with Specific Genetic Features

FDA Expands Approval of Pembrolizumab for First-Line Treatment of Non-Small Cell Lung Cancer

FDA Approves Pembrolizumab for Hodgkin Lymphoma

Pembrolizumab Shows Promise in Patients with Rare Form of Skin Cancer

Lung Cancer Precision Medicine Trials: Adapting to Progress

Pembrolizumab Improves Progression-Free Survival in Patients with Ipilimumab-Resistant Melanoma

The Playing Field for Cancer Checkpoint Inhibitors Is Expanding

Pembrolizumab Improves Overall Survival in Patients with Advanced Melanoma

Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker

New Therapies Are Changing the Outlook for Advanced Melanoma

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Pembrolizumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted: September 18, 2014
  • Updated: October 13, 2017